Researchers at the Medical University of South Carolina (MUSC) reported that the asthma medication formoterol may reverse fatty liver disease biology, including metabolic dysfunction-associated steatohepatitis (MASH). The work suggests the long-used L-type calcium channel blocker could alter disease-relevant pathways in models associated with MASH progression. The findings position formoterol as a repurposing candidate for liver inflammation and metabolic dysfunction, leveraging a drug class already characterized in respiratory indications. While details of study design were not included in the article summary, the report frames the results as a new therapeutic avenue for a condition with major unmet need and substantial burden. For the biotech and pharma pipeline, the development reinforces the ongoing strategy of identifying systemic effects of well-characterized drugs and mapping them to liver outcomes, potentially shortening the time from target biology to clinical testing.